{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:52:26Z","timestamp":1786978346132,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T00:00:00Z","timestamp":1169596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2007,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate disease reactivation in patients with Langerhans cell histiocytosis (LCH) and its impact on adverse sequelae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A retrospective evaluation of 300 patients diagnosed with LCH between 1987 and 2002 with complete response to initial treatment was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean age at diagnosis was 5.3 years. With a mean follow\u2010up of 4.8 years, reactivation of the disease occurred in 29.7% (89\/300) of the patients, with two or more reactivations in 34.8% (31\/89) of those. Reactivation occurred in 17.4, 36.8, 46.5, and 53.5% of the patients with single\u2010system unifocal disease (Group A: 161 patients), single\u2010system multifocal disease (Group B: 53 patients), multi\u2010system disease without (Group C: 58 patients), and with (Group D: 28 patients) risk\u2010organ involvement, respectively. The differences between the incidence rates of Groups A and B (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0004), A and C (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and A and D (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) were highly significant. The most common reactivation sites involved were bone, middle ear, and skin; reactivation was rare in risk organs (9.5%). The median time between initial complete response and the first reactivation episode was 1 year for Group A, 1.3 years for Group B, and 9 months for Groups C and D. Most reactivation episodes (88%) occurred within the first 2 years of follow\u2010up. Adverse sequelae were recognized in 242\/300 patients: 71% (49\/69) of patients with and 25.4% (44\/173) without reactivations developed these adverse sequelae (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), respectively. Sites most commonly showing sequelae were bone, middle ear, and hypothalamus (Diabetes Insipidus).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Incidence of reactivation correlates with the stage of the disease at diagnosis. Incidence of sequelae correlates with the occurrence of reactivations. Pediatr Blood Cancer 2007;48:696\u2013699. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pbc.21145","type":"journal-article","created":{"date-parts":[[2007,1,25]],"date-time":"2007-01-25T00:09:34Z","timestamp":1169683774000},"page":"696-699","source":"Crossref","is-referenced-by-count":52,"title":["Reactivation and risk of sequelae in Langerhans cell histiocytosis"],"prefix":"10.1002","volume":"48","author":[{"given":"Daniel","family":"Pollono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Latella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Chantada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Braier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,24]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"247","volume-title":"Hematology\/oncology clinics of North America","author":"Arico M","year":"1998"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(75)80576-2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2278::AID-CNCR25>3.0.CO;2-U"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20021"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20364"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-693X(96)80012-1"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2073"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.05.031"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230203"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230207"},{"key":"e_1_2_6_12_2","first-page":"327","volume-title":"Langerhans cell histiocytosis. Hematology oncology clinics of North America","author":"Broadbent V","year":"1998"},{"key":"e_1_2_6_13_2","first-page":"289","article-title":"Histiocytosis X","volume":"121","author":"Lucaya D","year":"1971","journal-title":"Am J Dis Child"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950240407"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.75.1.17"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.111331"},{"key":"e_1_2_6_17_2","first-page":"24771","article-title":"Langerhans cell histiocytosis (histiocytosis X) of bone: A clinicopathologic analysis of 263 pediatric and adult cases","volume":"76","author":"Kilpatrich SE","year":"1995","journal-title":"Cancer"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/088800199276921"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1178"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.01125.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511545252.007"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.21145","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.21145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T08:40:56Z","timestamp":1696840856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.21145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,24]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,6,15]]}},"alternative-id":["10.1002\/pbc.21145"],"URL":"https:\/\/doi.org\/10.1002\/pbc.21145","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,24]]}}}